Swiss Diversified Financial Stock News

Recent share performance and business overview SMG Swiss Marketplace Group Holding (SWX:SMG) has drawn interest after a period of weaker share performance, with the stock closing at CHF 26.35 and showing negative returns over the past week, month and past 3 months. The company runs online marketplaces across real estate, automotive and general classifieds in Switzerland. It earned CHF 358.843m in revenue and CHF 67.694m in net income, supported by reported annual revenue and net income growth...

Givaudan, ticker SWX:GIVN, is participating in the Future Food-Tech San Francisco event. The company is highlighting its front end innovation capabilities, with its Head of Front End Innovation presenting. The event participation puts a spotlight on Givaudan's role in emerging food technology trends and potential collaboration opportunities. Givaudan enters this conference with its share price at CHF2,701.0 and a value score of 4, reflecting how some investors may currently view the stock...

Swissquote Group Holding (SWX:SQN) has put up a busy FY 2025 scorecard, with second half revenue of CHF 388.1 million and basic EPS of CHF 13.88 sitting alongside trailing twelve month revenue of CHF 760.8 million and EPS of CHF 24.49, underpinned by reported earnings growth of 24.6% over the last year. The company has seen revenue move from CHF 356.9 million in the second half of 2024 to CHF 372.7 million in the first half of 2025 and CHF 388.1 million in the second half of 2025, while net...

Swatch Group (SWX:UHR) has delivered a soft set of FY 2025 numbers, with second half revenue of CHF 3.2b and net income excluding extra items of essentially break even, alongside a current share price of CHF 164.45. The company has seen half year revenue move from CHF 3.3b in second half 2024 to CHF 3.1b in first half 2025 and CHF 3.2b in second half 2025. Net income excluding extra items shifted from CHF 57m to CHF 3m and then to zero over the same periods, setting up a story where wafer...

Roche Holding's Ionify steroid assays for mass spectrometry have received U.S. FDA moderate complexity classification, widening access to advanced steroid hormone testing in clinical labs. Roche Pharma India has signed an MoU with NIPER Raebareli to collaborate on pharmaceutical education and research. These developments relate to both Roche's diagnostics portfolio and its global R&D footprint, including activity in India. Roche Holding (SWX:ROG) is drawing attention with regulatory...

SMG Swiss Marketplace Group Holding (SWX:SMG) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 175.8 million and basic EPS of CHF 11.48, providing a clear reference point against last year’s CHF 152.2 million in revenue and CHF 8.99 EPS for the same period. The company has seen revenue move from CHF 152.2 million to CHF 175.8 million and EPS shift from CHF 8.99 to CHF 11.48 year on year for the first half. Trailing 12 month figures show EPS ranging between CHF...

On 12 March 2026, Swiss Life Holding AG reported full-year 2025 results showing net income of CHF 1,234 million and slightly higher earnings per share, while also announcing an annual dividend of CHF 36.50 per share payable on 13 May 2026. The combination of steady profit growth and a higher cash distribution offers fresh insight into how Swiss Life balances shareholder returns with capital needs. With Swiss Life pairing higher earnings per share and an increased CHF 36.50 dividend, we’ll...

Julius Bär Gruppe (SWX:BAER) has posted its FY 2025 results with second half revenue of CHF 1,950.2 million and basic EPS of CHF 2.28, while trailing twelve month revenue came in at CHF 3,760.4 million and EPS at CHF 3.72. Over recent periods the bank has seen revenue move from CHF 1,916.3 million in the second half of 2024 to CHF 1,810.2 million in the first half of 2025 and then to CHF 1,950.2 million in the latest half, alongside EPS shifting from CHF 2.78 to CHF 1.44 and then CHF 2.28...

If you are wondering whether Partners Group Holding is attractively priced today, you are not alone. Many investors are trying to work out if the current share price reflects its long term potential. The stock closed at CHF 811.60, with returns of 1% decline over the last 7 days, 14.7% decline over 30 days, 21.2% decline year to date, and 35.9% decline over 1 year, while the 3 year return stands at 21.3% and the 5 year return at 15.6% decline. These moves have played out against a steady...

Earlier this month, ALSO Holding AG’s Board of Directors approved a share repurchase program of up to 9.74% of its capital for €120 million, aiming to use the treasury shares for acquisitions, liquidity, and long‑term management incentives. Around the same time, the company launched an AI Competence Center to help its partner network sell AI solutions, underscoring its focus on Microsoft 365 Copilot and the broader European AI ecosystem. We will now examine how the launch of the AI...

If you are wondering whether Cosmo Pharmaceuticals at around CHF 87.00 is still offering value after a solid run, this article walks through what the current price might be implying about the company. The stock has pulled back recently, with a 19.0% decline over the last 7 days and a 24.6% decline over the last 30 days, even though the 1 year return sits at 66.3% and the 3 year return at 70.4%. These moves come against a backdrop where investors are reassessing prior gains and weighing Cosmo...

In early March 2026, Giatec Scientific announced a commercial partnership with Sika to integrate Giatec’s AI-powered concrete sensors, software, and data tools into Sika’s global concrete product offering, supporting the Fast Forward program that targets an incremental EBITDA contribution of CHF 150.00 to 200.00 million by 2028. This move expands Sika’s digital capabilities across the concrete value chain, giving its customers access to real-time, AI-driven mix optimization and monitoring...

Partners Group Holding (SWX:PGHN) opened FY 2025 with first half revenue of CHF 1.2b and basic EPS of CHF 22.24, setting the tone for another data rich year of results. The company has seen revenue move from CHF 964.3m in the first half of 2024 to CHF 1.15b in the second half of 2024 and then to CHF 1.16b in the first half of 2025, while basic EPS shifted from CHF 19.52 to CHF 23.89 and then to CHF 22.24 over the same periods. With trailing net profit margins described at 49.2% compared with...

SIG Group (SWX:SIGN) is back in focus after its latest full year results showed sales of €3,248.7 million and a shift from €194.5 million net income to a €87 million net loss. See our latest analysis for SIG Group. The earnings release has come after a mixed stretch for the stock, with a 90 day share price return of 25.65% and a 1 year total shareholder return decline of 31.77%. This suggests recent momentum has improved while longer term returns remain weak as investors reassess the risk...

If you have been wondering whether Roche Holding shares are now offering good value or pricing in a lot of optimism, you are not alone. The stock last closed at CHF 332.40, with a 7 day return of an 8.4% decline, a 30 day return of a 6.7% decline, a 1 year return of 11.7% and a 3 year return of 40.4%. Recent moves in the share price sit against ongoing attention on Roche Holding as a major healthcare group, including continuing focus on its pharmaceuticals and diagnostics businesses and...

Cosmo Pharmaceuticals (SWX:COPN) has kicked off FY 2025 with first half revenue of €51.7 million and a basic EPS loss of €0.13, following FY 2024 second half revenue of €130.6 million with basic EPS of €3.45 and first half 2024 revenue of €136.2 million with basic EPS of €4.42. Over the trailing twelve months in the data, revenue is €182.3 million with basic EPS of €3.68. Investors may focus on how the latest dip into a small loss fits against a period where margins and earnings have...

Why the Bichsel decision matters for Galenica shareholders Galenica (SWX:GALE) has launched a consultation process on a planned production closure at its Bichsel subsidiary, a move that could affect up to 170 jobs by the end of 2026. The company plans to support affected employees with financial assistance, career guidance, and potential alternative roles within the wider Galenica network. A final decision is expected after the consultation concludes in mid March 2026. See our latest analysis...

Alcon reports that more than 175 million of its intraocular lenses have been implanted worldwide. The milestone highlights broad adoption of the company’s presbyopia-correcting IOLs across global eye care practices. Alcon plans further intraocular lens launches, subject to regulatory approvals. For investors following Alcon (SWX:ALC), this update comes with the shares trading at CHF63.96 and a value score of 4. The stock shows a 22.3% decline over the past year, while 3-year and 5-year...

Avolta AG recently completed the cancellation of about 4.9 million treasury shares, reducing its registered share capital to CHF 708,241,695 across 141,648,339 shares, while continuing to expand its food and beverage footprint at key airports in Italy and Canada. This combination of a tighter share base and integrated travel retail and dining growth highlights Avolta’s focus on capital efficiency alongside strengthening its airport partner relationships. Next, we’ll examine how Avolta’s...

Zurich Insurance Group has confirmed the acquisition of UK based insurer Beazley, following completion of an accelerated equity offering to fund the deal. The transaction expands Zurich's presence in international insurance markets and follows investor backing via fresh equity capital. The company, trading as SWX:ZURN, remains in focus as integration plans and capital impacts come into view for shareholders. Zurich Insurance Group, ticker SWX:ZURN, is approaching this deal with a current...

dormakaba Holding (SWX:DOKA) moved into focus after its H1 2026 results, reporting sales of CHF 1,362.7 million and net income of CHF 40.5 million, both below the prior half year. See our latest analysis for dormakaba Holding. The H1 2026 earnings release helps explain why the 90 day share price return sits at a decline of 13.01%, even though the 3 year total shareholder return is a gain of 41.09% and recent momentum has weakened despite a 3.60% 1 day share price return to CHF57.5. If this...

Sulzer AG has reported its full-year 2025 results, with sales of CHF 3,555.4 million, net income of CHF 292.8 million, and record EBITDA of CHF 556 million, marking a third consecutive year of margin expansion despite currency and geopolitical pressures. An increased dividend, a higher-margin aftermarket business now contributing 62% of turnover, and record profitability across divisions highlight how Sulzer’s operational excellence and services focus are reshaping its earnings...

Clariant (SWX:CLN) just posted its FY 2025 numbers with first half revenue of CHF 1,981 million and basic EPS of CHF 0.08, setting a cautious tone against a backdrop of trailing 12 month revenue of CHF 3,915 million and a basic EPS loss of CHF 0.23. The company has seen revenue hold in a tight band from CHF 2,070 million in the first half of 2024 to CHF 2,082 million in the second half of 2024, alongside EPS moving from CHF 0.48 to CHF 0.26. This now feeds into a mixed margin picture for...

Julius Bär Gruppe (SWX:BAER) has appointed Winfried Daun as Global Head of Brand & Marketing in a newly created leadership role. The company has introduced new model portfolios for UK financial advisers as part of an expanded UK wealth management approach. Julius Bär Gruppe, a Swiss private banking group, focuses on wealth management services for high net worth and ultra high net worth clients. The new marketing appointment and the UK model portfolios arrive as many wealth managers look to...